Functional (non-ulcer) dyspepsia
NUD, functional dyspepsia, epigastric pain syndrome, postprandial distress · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic/recurrent epigastric pain, early satiety, postprandial fullness or burning with NO structural cause on endoscopy (Rome IV: epigastric pain syndrome and/or postprandial distress syndrome, >=3 months, onset >=6 months). Diagnosis of exclusion after alarm-feature assessment and H. pylori testing.
Red flags
- Dysphagia, odynophagia
- Unintentional weight loss
- GI bleeding / iron-deficiency anaemia
- Persistent vomiting, epigastric mass
- New dyspepsia age >55
- Progressive/nocturnal pain, family history of upper GI cancer
Assessment
Differential diagnosis
- Peptic ulcer disease
- GORD
- Gastroparesis
- Biliary / pancreatic disease
- Gastric or oesophageal malignancy
- Coeliac disease, giardiasis
- Medication effect (NSAIDs, iron, metformin)
- Chronic mesenteric ischaemia (postprandial, weight loss, vascular risk)
Investigations
- Assess ALARM features (dysphagia, weight loss, anaemia, GI bleed, vomiting, mass, age >55 new-onset)
- H. pylori test-and-treat (stool antigen or urea breath test) - key first step in those without alarm features
- FBC, ferritin, coeliac serology (tTG-IgA), U&E, LFTs, calcium, glucose/HbA1c, TFTs
- Upper GI endoscopy if alarm features, age >55 with new dyspepsia, or refractory to initial therapy
- Consider abdominal USS if biliary features; lipase if pancreatic concern
Management
- Confirm no alarm features; if present -> urgent OGD (2-week-wait pathway if red flags)
- H. pylori test-and-treat: eradicate if positive (modest but real symptom benefit)
- If H. pylori negative or symptoms persist after eradication: 4-8 week PPI trial
- Review and stop culprit drugs (NSAIDs); lifestyle - smaller meals, reduce fat/caffeine/alcohol, weight loss, smoking cessation
- If PPI fails: trial prokinetic (postprandial distress phenotype) and/or neuromodulator
- Address psychological comorbidity; explain gut-brain axis and benign nature to reduce anxiety and re-investigation
- Refer gastroenterology if refractory, diagnostic uncertainty, or overlap with gastroparesis
Drugs & doses
Omeprazole 20-40 mg PO once daily 4-8 weeks (first-line pharmacotherapy, esp. epigastric pain/burning phenotype)
H. pylori eradication if positive (see PUD protocol - bismuth quadruple 14 days)
Prokinetic for postprandial distress: domperidone 10 mg PO TDS before meals, short course (QT caution, max ~1 week per MHRA) [verify local]
Metoclopramide 10 mg PO TDS (limit to 5 days - extrapyramidal risk) as alternative prokinetic
Tricyclic neuromodulator (refractory, esp. epigastric pain syndrome): amitriptyline 10-25 mg PO at night, titrate slowly
Mirtazapine 15 mg PO at night considered for early satiety/weight loss phenotype [verify local]
Avoid long-term NSAIDs; stop culprit drugs
Disposition
Outpatient / primary care. Gastroenterology referral only for alarm features, refractory symptoms, or diagnostic uncertainty.
Complications & pitfalls
- Reduced quality of life, anxiety/depression overlap
- Overlap with IBS and GORD
- Repeated unnecessary investigation if diagnosis not communicated
- Missed organic disease if alarm features not reassessed
Exam pearls
- ACG/CAG 2017 and Rome IV: in patients <60 (UK <55) without alarm features, H. pylori test-and-treat first, then empiric PPI - endoscopy is not required up front.
- Prokinetics suit the postprandial distress phenotype; PPIs suit the epigastric pain/burning phenotype.
- TCAs (amitriptyline) are effective neuromodulators in refractory functional dyspepsia; SSRIs are not.
- A positive, confident diagnosis with explanation reduces repeat investigation and improves outcomes.
- Re-screen for alarm features at each review - functional dyspepsia is a diagnosis of exclusion.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.